An observational study in Ischemic Stroke, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 33 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-16.
Sponsored by Insel Gruppe AG, University Hospital Bern · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Ischemic Stroke by Insel Gruppe AG, University Hospital Bern — 7 open to participants now, 7 under way, none of them phase 3. Ischemic Stroke · Insel Gruppe AG, University Hospital Bern.
Among the 16 studies in Ischemic Stroke by Insel Gruppe AG, University Hospital Bern, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2024, is one of 11 observational ones, and was the 13th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →7 of the 16 studies in Ischemic Stroke by Insel Gruppe AG, University Hospital Bern are open now, in 12 countries. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Austria, Belgium, Canada and 9 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Belgium, Germany, New Zealand and 3 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
By country, each count listing its studies:
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,800 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Median enrollment 482 across the 5 interventional studies, 370 across the 11 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.
1 of the studies in Ischemic Stroke by Insel Gruppe AG, University Hospital Bern that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06691230Insel Gruppe AG, University Hospital BernPeRfusiOn Post tHrombEcTomy (PROPHET) | 2027-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Ischemic Stroke by Insel Gruppe AG, University Hospital Bern, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
DO-IT is an international, prospective observational registry evaluating whether the administration of intravenous thrombolysis (IVT) is safe and improves functional outcome in ischemic stroke patients with recent direct oral anticoagulant (DOAC) intake. For this purpose, information on 2800 adult participants experiencing an acute ischemic stroke will be obtained at several high-volume international stroke centers and divided into three groups: IVT with recent DOACs intake (DOAC+IVT), and recent DOAC intake not receiving IVT (DOAC) as well as anonymized patients without DOAC receiving IVT. The patients are followed up for 90 days after the index event. treatment recommendations from the described observations. The investigators hypothesize that also more liberal decisions for IVT in patients with recent DOAC intake are not associated with an increased risk for symptomatic intracerebral hemorrhage (sICH) and result in better functional outcome at 3 month.
The in- and exclusion criteria emulate a target trial, thus the investigators want to study a population that is - except from recent DOAC ingestion - eligible for IVT as per standard of care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acute ischemic Stroke patients with recent DOACs intake receive IVT.
Drug: Tenecteplase and Alteplase
Acute ischemic Stroke patients with recent DOAC intake do not receive IVT.
Acute ischemic Stroke patients without recent DOAC intake receive IVT.
Drug pages: TenecteplaseStudies of TenecteplaseTenecteplase pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Tissue Plasminogen ActivatorStudies of Tissue Plasminogen ActivatorTissue Plasminogen Activator pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
The timepoints, dose, and type of IVT will be collected as well as any complications occuring.
Number of Participants with symptomatic intracerebral hemorrhage (sICH)
Defined as worsening of at least 4 points on the National Institutes of Health Stroke Scale and attributed to radiologically evident intracranial hemorrhage.
Time frame: Within 36 hours after IVT
Dichotomized good functional outcome (mRS 0-2)
Modified Rankin Scale from 0 (no disability) to 6 (death)
Time frame: At day 90 or return to baseline (+/- 2 weeks) after admission
Rate of IVT among IVT-eligible DOAC patients
To determine the rate of IVT in eligible patients with acute ischemic stroke and recent DOAC intake.
Time frame: Through study completion, an average of 2 years
All-cause mortality, major bleeding and orolingual edema
Time frame: From date of randomization until the date of all-cause mortality, major bleeding or orolingual edema, whichever came first, assessed up to 7 days.
Categorical shift in the modified Rankin Scale (mRS)
Modified Rankin Scale from 0 (no disability) to 6 (death)
Time frame: At Day 90 (+/-2 weeks) after admission
Stroke severity (NIHSS)
National Institutes of Health Stroke Scale from 0 (no symptoms) to 39 (most severe symptoms)
Time frame: At 24 hours ±8 hours
Ischemic stroke volume at 24 hours (mL)
Time frame: At 24 hours ±8 hours
Plan to share: Yes — IPDMA of similar observational cohort studies is planned.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: After publication of primary study results
Access criteria: Ethics clearance, agreement with the DO-IT collaboration about terms of use and authorship
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Mar 2026, 26 months after the start.
Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 26 months is below that.
Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →